SCHEMBL278010

SCHEMBL278010

CCN1c2ccc(S(=O)(=O)O)cc2SC1NC1Sc2cc(S(=O)(=O)O)ccc2N1CC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EP300 Q09472 1/20 0.36
▸ ALDH1A1 P00352 5/20 0.33
▸ LMNA P02545 3/20 0.33
▸ MAPT P10636 3/20 0.33
▸ GAA P10253 2/20 0.33
▸ CA1 P00915 2/20 0.32
▸ CA2 P00918 2/20 0.32
▸ CA12 O43570 1/20 0.32
▸ CA7 P43166 1/20 0.32
▸ CA14 Q9ULX7 1/20 0.32
▸ CASP6 P55212 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ SNCA P37840 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ PKM P14618 1/20 0.31
▸ RXFP1 Q9HBX9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30600023 1.00 EP300 (0.36) EP300ALDH1A1LMNAMAPTGAA
Ammonia Solution, Strong SCHEMBL14121026 0.99 EP300 (0.36) EP300ALDH1A1LMNAMAPTGAA
Ammonia Solution, Strong SCHEMBL4563062 0.99 EP300 (0.36) EP300ALDH1A1LMNAMAPTGAA
SCHEMBL16195480 0.83 EP300 (0.35) EP300ALDH1A1LMNAMAPTGAA
SCHEMBL28927324 0.82 ALDH1A1 (0.34) EP300ALDH1A1LMNAMAPTGAA
SCHEMBL7585449 0.82 ALDH1A1 (0.33) EP300ALDH1A1LMNAMAPTGAA
SCHEMBL6421977 0.81 ALDH1A1 (0.34) EP300ALDH1A1LMNAMAPTGAA
SCHEMBL969169 0.81 ALDH1A1 (0.34) EP300ALDH1A1LMNAMAPTGAA
SCHEMBL361931 0.81 ALDH1A1 (0.34) EP300ALDH1A1LMNAMAPTGAA
Ammonia Solution, Strong SCHEMBL28851102 0.80 ALDH1A1 (0.33) EP300ALDH1A1LMNAMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3303572-B1 DETERGENTS WITH IMPROVED DETERGENT POWER, CONTAINING AT LEAST ONE LACCASE HENKEL AG & CO KGAA (DE) 2019-08-07 — — EP claimed
US-8470549-B2 Method for detecting an antigen PANASONIC CORPORATION (JP) 2013-06-25 — — US claimed
US-5766896-A Method of producing iodine by use of a copper containing oxidase enzyme NOVO NORDISK BIOTECH INC. (US) 1998-06-16 — — US claimed
JP-63185397-A — — None — — JP disclosed
US-11998608-B2 Polysaccharide and methods THE SECRETARY OF STATE FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS (GB) 2024-06-04 — — US disclosed
EP-3227438-B1 LACCASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME NOVOZYMES AS (DK) 2024-03-27 — — EP disclosed
EP-3617229-B1 DETECTION REAGENT AND KIT FOR IDENTIFYING ACIDIC STATE AND GLYCATION STATE OF LOW DENSITY LIPOPROTEIN YAMADA KEN ICHI (JP) 2024-03-13 — — EP disclosed
WO-2023224465-A1 INSECT FAT FOR IMPROVING INTESTINAL IMMUNITY PROTIX B.V. (NL) 2023-11-23 — — WO disclosed
WO-2023224464-A1 INSECT FAT FOR USE IN THE TREATMENT OR PROPHYLAXIS OF INTESTINAL INFLAMMATION PROTIX B.V. (NL) 2023-11-23 — — WO disclosed
US-11801210-B2 Retinol replacement in skin treatment SYMRISE AG (DE) 2023-10-31 — — US disclosed
EP-4259088-A1 COSMETIC AND/OR PHARMACEUTICAL COMPOSITIONS CONTAINING CANNABINOIDS Symrise AG (DE) 2023-10-18 — — EP disclosed
US-5494672-A HAVING SEQUENCE CORRESPONDING TO C-TERMINAL PORTION OF THE PSEUDOMONAS AERUGINOSA PILIN PROTEIN; VACCINE S.P.I. SYNTHETIC PEPTIDES INCORPORATED (CA) 1996-02-27 — — US disclosed
EP-0349113-B1 Monoclonal antibody against human manganese-superoxide dismutase, method for producing the monoclonal antibody, assay reagent or assay kit and assay method by use thereof, and diagnostic method of human ovarian cancer and myocardial infarction by use thereof UBE INDUSTRIES (JP) 1995-03-01 — — EP disclosed
US-5288746-A Liquid laundry detergents containing stabilized glucose/glucose oxidase as H2 O2 generation system THE PROCTER & GAMBLE COMPANY (US) 1994-02-22 — — US disclosed
EP-0567470-A1 PSEUDOMONAS PEPTIDE COMPOSITION AND METHOD FOR PRODUCING THE SAME S.P.I. SYNTHETIC PEPTIDES INCORPORATED (CA) 1993-11-03 — — EP disclosed
EP-0261591-B1 METHOD FOR ASSAYING 1,5-ANHYDROGLUCITOL AND KIT THEREFOR NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1993-03-10 — — EP disclosed
US-5147783-A Analyzing for superoxide dismutase UBE INDUSTRIES, LTD. (JP) 1992-09-15 — — US disclosed
US-5115097-A Synthetic peptide from the carboxy terminal of human Mn-superoxide dismutase UBE INDUSTRIES, LTD. (JP) 1992-05-19 — — US disclosed
US-4994377-A Separate containers of basic anion exchange resin for sugar removal, hydrogen peroxide detector, oxidase NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1991-02-19 — — US disclosed
US-4634663-A ENZYMATIC OXIDATION NODA INSTITUTE FOR SCIENTIFIC RESEARCH (JP) 1987-01-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11801210-B2 Retinol replacement in skin treatment RBP1, RBP4, LRAT EP300 2083/4885ALDH1A1 22/4885LMNA 1793/4885
US-11998608-B2 Polysaccharide and methods CAP1, C1S, DDOST EP300 1986/4885ALDH1A1 3609/4885LMNA 1108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback